Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Key mutation sites in the SARS-CoV-2 spike protein modulate antibody and ACE2 affinity

A paper recently uploaded to the preprint server bioRxiv by researchers at Chapman University in California (Feb 22nd, 2021) utilized computational methods to screen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants for affinity with the angiotensin-converting enzyme 2 (ACE2) receptor and monoclonal antibodies REG10987 and REG10933.

23 Feb 2021

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

A new research paper recently uploaded to the preprint server bioRxiv by Jesse D. Bloom et al. (22nd Feb 2021) aims to map all of the currently circulating SARS-CoV-2 lineages with resistance towards LY-CoV555 and LY-CoV016, and document the specific mutations that confer resistance, ultimately suggesting that future monoclonal antibody cocktails should target a more diverse range of epitopes.

23 Feb 2021

GSK-3 inhibitors show promise in treating coronavirus infections

Researchers in the United States have suggested a new approach to treating infection with coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

23 Feb 2021

Glycan switch may explain why SARS-CoV-2 causes such variable symptoms

Researchers in Portugal have provided evidence that might explain why infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes mild or even asymptomatic illness in some individuals, but severe coronavirus disease 2019 (COVID-19) in others.

23 Feb 2021

Researchers develop nanoceutical mask fabric that prevents SARS-CoV-2 transmission

Researchers at S N Bose National Centre for Basic Sciences in West Bengal found that a nanoceutical fabric, which is comfortable, washable, and anti-microbial, can prevent the transmission of SARS-CoV-2.

23 Feb 2021

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The model has induced angiotensin-converting enzyme 2 (ACE2) blocking antibodies in mice.

23 Feb 2021

Incidence of cardiometabolic and pulmonary events in UK has lowered due to COVID-19

A team of researchers from the University of Oxford, the London School of Hygiene and Tropical Medicine and other institutions recently analyzed extensive data collected by NHS England to reveal any association between SARS-CoV-2 infection and cardiometabolic or respiratory events.

23 Feb 2021

How effective has Israel’s SARS-CoV-2 testing and vaccination campaign been against the UK variant?

A recent study by researchers at Tel Aviv University describes the UK variant’s rise to dominance in Israel. It also assesses the efficacy of the testing and vaccination programs employed by the government.

23 Feb 2021

L452R mutation potentially favors adaptive evolution of SARS-CoV-2

A team of scientists from the United States recently investigated the mutational signatures in the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.

23 Feb 2021

Countries with older populations have higher SARS-CoV-2 infections and deaths, says study

A new study examines some patterns revealed by a study of the factors operating in different regions and countries, to offer plausible hypotheses of these variations.

23 Feb 2021

Cannabinoid receptor agonist shows potential protective effect on SARS-CoV-2-infected human heart cells

As scientists continue to search for effective antidotes to direct and indirect damage caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server demonstrates the potential of cannabinoid receptor agonists to alleviate myocardial damage in this condition even in the absence of any inhibitory effect on viral infection as such.

23 Feb 2021

Influenza A virus defective interfering particles against SARS-CoV-2

In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.

23 Feb 2021

Virus-specific cellular immunity may be essential for long-term protection against SARS-CoV-2

Researchers from China and the US recently synthesized select peptide pools of the structural and functional proteins of SARS-CoV-2, including spike (S), envelope (E), membrane (M), nucleocapsid (N), and protease (P) proteins as target antigens to assess COVID-19-specific immunity.

22 Feb 2021

Seropositive individuals show similar antibody levels to a second mRNA vaccine dose

Seropositive individuals —people who received antibodies after COVID-19 infection — may be able to safely delay their second mRNA vaccine dose after all, according to the results of a new study.

22 Feb 2021

No evidence of SARS-CoV-2 fusing into the human genome

New data from researchers led by Majid Kazemian from Purdue University refutes claims from recent studies suggesting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could create a host-virus chimeric RNA. Their team found SARS-CoV-2 does not combine with the human genome.

22 Feb 2021

Research identifies failures with Australia and New Zealand's hotel-based COVID-19 quarantine

The researchers found a notable risk of failure with hotel quarantine in Australia and New Zealand. The two countries have collectively had 16 COVID-19 identified failures from hotel-based quarantine up to January 31, 2021. The two countries also have higher proportions of infected travelers, threatening both nations' status in eliminating the illness.

22 Feb 2021

Current monoclonal antibodies less potent against SARS-CoV-2 variants

Researchers at the New York University Grossman School of Medicine and Biohaven Pharmaceuticals found that the REGN10933 and REGN10987 combination was 9.1-fold less potent on the B.1.351 variant, which emerged in South Africa, and 16.2-fold less potent on mink cluster 5.

22 Feb 2021

Applications of Artificial Intelligence in COVID-19 ICU and ER situations

The overwhelming increase in critically ill COVID-19 patients, who urgently require intensive care units (ICU) and emergency departments (ED), has challenged healthcare systems worldwide.

22 Feb 2021

Failed antiviral response in nasal mucosa may predict severe COVID-19

Researchers in the United States have conducted a study suggesting that the host response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within nasal mucosa is a key determinant of clinical trajectory in coronavirus disease 2019 (COVID-19).

22 Feb 2021

Viral protein delivery system could facilitate COVID-19 research

Researchers in the United States have successfully delivered a critical structural protein found in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to a human cell line and tracked its localization deep within the cells.

22 Feb 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Key mutation sites in the SARS-CoV-2 spike protein modulate antibody and ACE2 affinity

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

GSK-3 inhibitors show promise in treating coronavirus infections

Glycan switch may explain why SARS-CoV-2 causes such variable symptoms

Researchers develop nanoceutical mask fabric that prevents SARS-CoV-2 transmission

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Incidence of cardiometabolic and pulmonary events in UK has lowered due to COVID-19

How effective has Israel’s SARS-CoV-2 testing and vaccination campaign been against the UK variant?

L452R mutation potentially favors adaptive evolution of SARS-CoV-2

Countries with older populations have higher SARS-CoV-2 infections and deaths, says study

Cannabinoid receptor agonist shows potential protective effect on SARS-CoV-2-infected human heart cells

Influenza A virus defective interfering particles against SARS-CoV-2

Virus-specific cellular immunity may be essential for long-term protection against SARS-CoV-2

Seropositive individuals show similar antibody levels to a second mRNA vaccine dose

No evidence of SARS-CoV-2 fusing into the human genome

Research identifies failures with Australia and New Zealand's hotel-based COVID-19 quarantine

Current monoclonal antibodies less potent against SARS-CoV-2 variants

Applications of Artificial Intelligence in COVID-19 ICU and ER situations

Failed antiviral response in nasal mucosa may predict severe COVID-19

Viral protein delivery system could facilitate COVID-19 research

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Newsletters you may be interested in